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Abstract
Background: Patient outcomes can depend on the treating centre, or health professional, delivering the
intervention. A health professional’s skill in delivery improves with experience, meaning that outcomes may be
associated with learning. Considering differences in intervention delivery at trial design will ensure that any
appropriate adjustments can be made during analysis. This work aimed to establish practice for the allowance of
clustering and learning effects in the design and analysis of randomised multicentre trials.
Methods: A survey that drew upon quotes from existing guidelines, references to relevant publications and
example trial scenarios was delivered. Registered UK Clinical Research Collaboration Registered Clinical Trials Units
were invited to participate.
Results: Forty-four Units participated (N = 50). Clustering was managed through design by stratification, more
commonly by centre than by treatment provider. Managing learning by design through defining a minimum
expertise level for treatment provider was common (89%). One-third reported experience in expertise-based
designs. The majority of Units had adjusted for clustering during analysis, although approaches varied. Analysis of
learning was rarely performed for the main analysis (n = 1), although it was explored by other means. The insight
behind the approaches used within and reasons for, or against, alternative approaches were provided.
Conclusions: Widespread awareness of challenges in designing and analysing multicentre trials is identified.
Approaches used, and opinions on these, vary both across and within Units, indicating that approaches are
dependent on the type of trial. Agreeing principles to guide trial design and analysis across a range of realistic
clinical scenarios should be considered.
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Background
Patient outcomes depend crucially on the treatment pro-
vider delivering the intervention. Where there is more
than one treatment provider, outcomes observed in pa-
tients treated by the same treatment provider may be
more similar than those in patients treated by other
treatment providers, a phenomenon known as clustering.
Whilst treatment providers are often thought of as
health professionals, such as general practitioners,
nurses, surgeons or therapists, the potential for cluster-
ing is also present for treating centre within a clinical
trial [1, 2]. In addition to clustering, a change in skill in
treatment delivery may be observed over time; specific-
ally, there may be a learning element experienced within
one or all of the arms of the study observed during the
course of the trial, meaning that trial outcomes may also
change and be associated with changes in skill [3]. When
comparing interventions within a clinical trial, it is im-
perative that any trial is designed under a common
protocol with regard to treatment delivery, and that the
trial is conducted in accordance with this protocol. At
trial outset, a researcher may consider the homogeneity
of any intervention under examination and the degree to
which it is appropriate to standardise these procedures
[4]. In extreme cases, where the trial results are ques-
tioned by the research community related to the study
results, the trial team should be prepared to alleviate any
doubts of heterogeneity of treatment effects [5].
Difference in treatment delivery is often considered
more of a concern in trials investigating a complex inter-
vention, such as surgery. Trials involving a complex inter-
vention are often criticised because of variability between
intervention providers (clustering) but also due to variabil-
ity over time, often as a result of increased experience
(learning) [4]. Recognition, and management as appropri-
ate, of clustering and learning is recommended, and it
may have increased relevance within the surgical field,
dependent upon the interventions being investigated and
their routine use [2, 4, 6–9]. Considering these aspects at
trial outset will ensure that any necessary adjustment, to
the design or analysis of the study, is applied in a manner
appropriate for the intervention under investigation and
will support clinical decision-making [5].
Whilst the notion of clustering and learning is familiar
to many statisticians, the extent to which these consider-
ations are made, and how, is unknown. A survey to estab-
lish current practice for the statistical management of
clustering and learning effects in the design and analysis
of randomised multicentre trials was undertaken within
UK Clinical Research Collaboration (UKCRC) Registered
Clinical Trials Units (CTUs) [10]. This survey aimed to as-
certain the UK-wide experience of running multicentre
studies, in particular those investigating a complex or sur-
gical intervention, in addition to establishing awareness of
design issues associated with these studies and levels of
concerns around these issues.
Methods
The survey was delivered at the bi-annual Statisticians
Operational Group Meeting in April 2018. Attendees
were statistical representatives from each of the UKCRC
Registered CTUs [10]. Units that did not have a repre-
sentative present at this meeting, or did not respond,
were contacted via email following the event and invited
to participate. Registered CTUs were identified from the
network website [10] on 4 January 2018 (n = 51, of
which 50 were registered at the time of survey; see Sup-
plementary Box 1). As the survey involved professionals
and discussions of current practice, no formal ethical ap-
provals were deemed necessary.
Survey
EJC and CG developed the survey, and GB, JMB and
JAC reviewed and provided feedback. The survey was
subsequently piloted and revised prior to roll out
(Supplementary Box 2).
This survey was developed to establish experience in
multicentre trials, in particular those investigating a
complex intervention. In order to contextualise the
survey content, questions drew upon quotes from exist-
ing guidelines, references to relevant publications and
example scenarios developed by the study team ([4, 9, 11],
Table 1). Questions included concepts such as CTUs’ ex-
perience in adjusting for clustering (therapist/surgeon or
centre) or time-varying effects (learning curves) and, when
a Unit had experience, when and how adjustments are
applied. This survey also aimed to establish awareness
about design issues in surgery and levels of concern
around these issues.
Questions were analysed and reported by Unit. To
represent Unit practice and experience as a whole, Units
with multiple responders were combined. In the case
Table 1 Example trial scenarios
Scenarios
A A trial with a largea sample size, recruiting in several centres, each
with multiple treatment providers
B A trial with a smallb sample size, recruiting in several centres, each
with multiple treatment providers
C A trial that recruits within several centres, where treatment providers
treat patients across recruiting centres; i.e. treatment provider is not
unique to a centre
D A trial recruiting from several centres, each with multiple treatment
providers, investigating a surgical intervention
E A trial recruiting from several centres, each with multiple treatment
providers, investigating substantially different surgical interventions,
e.g. a trial comparing surgery to an injection
aCentres recruiting at least 10 patients per site
bCentres recruiting 2 to 3 patients per site
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that multiple responders from a single Unit provided
contradictory answers, for example one responder stated
they had experience and another stated they did not, it
was assumed that the Unit had the experience. However,
due to the nature of the network meeting invites (one
per registered CTU), multiple responders from a single
CTU were minimised.
Analysis
Quantitative data from closed questions were analysed using
descriptive statistics with standard statistical software (Statis-
tical Analysis Software [SAS®] 9.1.4; SAS Institute Inc., Cary,
NC, USA); no formal statistical testing was undertaken.
Free text answers were used to contextualise and illu-
minate quantitative responses.
To ensure anonymity, each Unit was assigned a project
identification number.
Results
Unit participation and demographics
Forty-seven of the 50 UKCRC Registered CTUs were
represented at the network meeting on 28 April 2018.
Of those present, 34 representatives from 31 CTUs
(62%) participated. Following the meeting, Units without
a completed survey were contacted, of which 13
responded (n = 13/19). Supplementary Table 1 provides
further details. The overall participation rate of regis-
tered Units was 88% (n = 44/50). One representative
from a newly registered Unit reported lack of experience
as a reason for non-participation; reasons were not pro-
vided from the remaining five Units.
All responders had a statistical background, with the ma-
jority of responders holding a senior or lead at their Unit
(senior statistician: n = 15/44, 34%; statistical lead: n = 13/
44, 30%). Supplementary Table 2 provides further details.
CTUs listed on the UKCRC Resource Finder [10] as
conducting cluster or surgical trials had participation
rates of 94% (n = 16/17) and 92% (n = 33/36) respect-
ively (see Supplementary Table 3). CTUs with a meth-
odological research area in complex interventions
participated with a rate of 90% (n = 35/39).
Three-quarters of CTUs indicated experience in run-
ning trials with a complex intervention (n = 32/44, 73%)
and two-thirds in running trials with a surgical interven-
tion (n = 29/44, 66%), with 25 (57%) indicating experi-
ence in both. Seven CTUs stated that their Unit did not
have experience in running trials with either type of
intervention (n = 7/44, 16%). One did not respond to
this question (Question 1, Supplementary Table 4).
Managing effects through design
Clustering
Twenty-five Units had undertaken multicentre trials that
did not stratify by centre (n = 25/44, 57%; see Table 2,
Question 2, and Table 3). Common reasons for not
stratifying by centre were many centres with few partici-
pants (n = 19/25, 76%) and expected homogeneity of
treatment effect (n = 11/25, 44%). Additional reasons for
not stratifying by centre included allocation concealment
in an open trial; logistical reasons; and grouping centres
by region. One responder clearly indicated that this deci-
sion was influenced by the nature of the intervention,
stating:
“ … drug trials less effect due to centre compared to
say complex or surgical interventions.” [ID23]
One responder who did stratify all the Unit’s trials by
centre alluded to concerns regarding potential for un-
equal distribution of costs across centres:
“This subject gets a lot of academic debate in some
academic circles. But: our randomisation defaults to
stratifying by centre; need to balance resources—-
don’t want to give one too many overheads;
balancing avoids confounding; other opinions, such
as Torgerson, exist.” [ID8]
Question 3 asked responders to consider five scenarios
(Tables 1, 2 and Supplementary Table 5), in particular
their approach to stratifying the randomisation in trials
of each type run by their Unit. Responses to Scenario A,
of which 39 Units had experience, indicated that most
Units when running a trial with a large sample size, with
multiple treatment providers per centre each recruiting
a minimum of 10 participants, would stratify by centre
alone (n = 34/39, 87%).
Three would stratify by treatment provider alone (n =
3/39, 8%). Seventy percent had experience in running
trials like Scenario B, which was the same as Scenario A,
only with a small sample size (n = 31/44, 70%). As with
Scenario A, most Units ran such trials by stratifying by
centre alone (n = 24/31, 77%) and few by treatment pro-
vider alone (n = 2/31, 6%).
Responders had less experience running Scenario C
trials, trials recruiting in several centres where treatment
providers treated patients across centres (n = 16/44,
36%). Again, most common was stratification by centre
only (n = 14/16, 88%), with a greater number of Units
indicating that they had stratified such trials by treat-
ment provider only (n = 3/16, 19%).
CTUs with experience running trials in Scenario D, i.e.
trials recruiting from multiple centres, each with mul-
tiple treatment providers and investigating a surgical
intervention (n = 25/44, 57%), also primarily stratified by
centre only (n = 21/25, 84%). One-fifth indicated stratify-
ing by both centre and treatment provider in such trials
(n = 5/25, 20%).
Conroy et al. Trials          (2020) 21:433 Page 3 of 13
Table 2 Methods for managing clustering and learning by design
Question Category Response statistics
n N n/N%
2 Does your Unit have any multicentre trials that do not stratify
randomisation by centre?
Yes 25 44 57%
No 18 44 41%
See Table 4 for further details. No response 1 44 2%
3 In each of the following scenarios, how was the randomisation
stratified in trials that your Unit has run? Select all that apply.
See Supplementary Table 5 for further details.
A Large sample size,a recruiting in several centres, each with
multiple treatment providers
Experience in trial type 39 44 89%
Centre 34 39 87%
Treatment provider 3 39 8%
Both 10 39 26%
Neither 1 39 3%
No experience in trial type 4 44 9%
No response 1 44 2%
B Small sample size,b recruiting in several centres, each with
multiple treatment providers
Experience in trial type 31 44 70%
Centre 24 31 77%
Treatment provider 2 31 6%
Both 2 31 6%
Neither 7 31 23%
No experience in trial type 12 44 27%
No response 1 44 2%
C Recruiting in several centres, where treatment providers
treat patients across recruiting centres (treatment provider
is not unique to a centre)
Experience in trial type 16 44 36%
Centre 14 16 88%
Treatment provider 3 16 19%
Both 1 16 6%
Neither 0 16 0%
No experience in trial type 27 44 61%
No response 1 44 2%
D A trial investigating a surgical intervention, recruiting from
several centres, each with multiple treatment providers
Experience in trial type 25 44 57%
Centre 21 25 84%
Treatment provider 3 25 12%
Both 5 25 20%
Neither 3 25 12%
No experience in trial type 17 44 39%
No response 2 44 5%
E Recruiting from several centres, each with multiple treatment
providers, comparing substantially different interventions e.g.
surgery to an injection
Experience in trial type 16 44 36%
Centre 13 16 81%
Treatment provider 0 16 0%
Both 2 16 13%
Neither 2 16 13%
No experience in trial type 26 44 59%
No response 2 44 5%
In scenarios where Unit has experience, approaches to
stratification changes across scenario, i.e. within-Unit variation
to stratification
Different approaches across scenarios 20 44 46%
Same approach across all scenarios 19 44 43%
No response to Question 3 5 44 11%
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Whilst Units had less experience running trials like Sce-
nario E, which was similar to Scenario D but investigating
substantially different interventions, stratification approaches
were similar to those of Scenario D (centre only: 13/16, 81%;
both centre and treatment provider: 2/16, 13%).
Twelve responders provided free text explaining their
approaches for stratification in each of the scenarios
(Question 3, Supplementary Table 5). Two-thirds (n = 8/
12, 67%) commented on the feasibility of stratifying by
treatment provider. Reasons were as follows: concerns that
there would be too few per strata [ID8, ID15, ID39]; treat-
ment provider not known in advance [ID8, ID32]; deliv-
ered by a subset of treatment deliverers [ID1, ID39]; data
not collected on treatment provider [ID13]; treatment dif-
ferences assumed to be differences in facilities and proto-
cols [ID17]; usually comparing the intervention policy and
not the different aspects of the intervention [ID32]; treat-
ment provider can change during the trial [ID30].
Table 2 Methods for managing clustering and learning by design (Continued)
Question Category Response statistics
n N n/N%
4 In the trials run by your Unit, have you defined a minimum level
of expertise for the health professionals participating in the trial
in terms of:
Treating the condition within the patient population 24 44 55%
Delivering the trial intervention 31 44 70%
Setting a minimum professional level of treatment
providers
22 44 50%
Other approach:
Based on paramedic experience (defined by years
in service)
1 44 2%
Based on surgeon experience (at or beyond a
certain level)
1 44 2%
Centre required to conduct a certain number of
operations per year
1 44 2%
Clinical decision for Chief Investigator 1 44 2%
Deliverer required to pass surgical and
radiotherapy quality assurance
1 44 2%
Depends on phase of trial—early or pragmatic
require different levels
1 44 2%
In our stepwise study, all therapists were
experienced but the intervention was brand new
1 44 2%
Investigators who define research question are
experts in the field and have trained staff to deliver
intervention
1 44 2%
No consistent approach across all our studies. 1 44 2%
No Unit-wide policy—decided trial by trial
depending on intervention and setting
1 44 2%
Surgeon manuals signed off by ‘senior’ surgeon
prior to participation
1 44 2%
Surgical team led by consultant, who submits
video measured for quality assurance, prior to
participation
1 44 2%
These have been implicitly taken as a Chief
Investigator and Principal Investigator
1 44 2%
Training provided to health care professionals in
order to participate
1 44 2%
No, or no response 5 44 11%
5 Has your Unit conducted trials with an expertise-based design,
in which participating treatment providers provide only the
intervention in which they have expertise?
Yes, when applicablec 13 44 30%
No, with justification 1 44 2%
No 26 44 59%
No response 4 44 9%
aWith centres each recruiting at least 10 patients
bWith centres each recruiting 2 to 3 patients
cWe only have one grant application for which we’ve proposed an expertise-based design this year but no prior experience of running a trial with such a design
before [ID22]
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Other responses provided examples of stratification
levels, e.g. centre as hospital and treatment provider as
operating surgeon [ID10]; two that this was trial-specific
[ID14, ID29]. One raised concerns with stratifying by
centre:
“Recent conversions between senior statisticians
advocate not stratifying by centre in any situation.
They cited concerns regarding prediction of
allocation.” [ID18]
When comparing stratification approaches across sce-
narios within Units (Question 3, Table 2), 19 Units used
the same approach across all scenarios in which they
had experience, and 20 changed their approach depend-
ing on the trial scenario (same: n = 19/44, 43%; different:
n = 20/44, 46%). Five had no experience in any of the
suggested scenarios or did not respond to the question.
Learning
The majority of responders (n = 39/44, 89%) indicated
they had accounted for learning by defining a minimum
level of expertise for treatment providers (Question 4,
Table 2). Common definitions were set in terms of deliv-
ering the trial intervention (n = 31/44, 70%); treating the
condition within the patient population (n = 24/44,
55%); and setting a minimum professional level for treat-
ment providers (n = 22/44, 50%). Three delegated this
responsibility to the clinical investigators on the study.
Examples of alternative approaches to specifying mini-
mum levels of expertise included use of a surgical man-
ual with senior surgeons signing off treatment deliverers
[ID15] and treatment deliverers being required to pass
both surgical and radiotherapy quality assurance [ID18].
Thirty percent of CTUs had used an expertise-based
trial design, in which participating treatment providers
provide only the intervention in which they have expert-
ise (n = 13/44, 30%, Question 5, Table 2).
Managing effects through analysis
Clustering
In trials stratified by centre, 55% of Units had subse-
quently adjusted by this stratification factor in the ana-
lysis (n = 24/44, 55%, Question 6, Tables 4 and 5). This
Table 3 Reasons for having multicentre studies that do/do not stratify by centre (Question 2)
Unit has multicentre trials that do not stratify randomisation by centre? Yes (N = 25) No (N = 18)
Reason(s) provided
Expected homogeneity of treatment effect across centres 11 44% 2 11%
No interest in centre effect 4 16% 1 6%
Lots of centres with few participants per centre 19 76% 1 6%
Not convinced of appropriateness of either fixed or random
effect models for centres in the trial
1 4% 0 0%
Other reason provided
Aids in blinding if trial open label 1 4% 0 0%
Balance against other important factors. Centre effect less
important in drug trials compared to complex or surgical
interventions
1 4% 0 0%
Concern that, in an unblinded trial, stratifying by centre
would make it easier to predict the treatment allocated to
the next patient [12] 16:405).
1 4% 0 0%
For practical reasons 0 0% 1 6%
Intervention takes place out of hospital 1 4% 0 0%
Large sample size with small/moderate number of centres.
We expect balance to be achieved with simple randomisation
1 4% 0 0%
Likely to stratify by geographical region if not by centre 1 4% 0 0%
Randomisation system defaults to stratifying by centre but
one example where minimised trial did not. Need to consider
balance of resources and avoid confounding. There is a lot of
academic debate. e.g. Torgerson.
0 0% 1 6%
Sometimes stratify by region 1 4% 0 0%
Stratified by treatment provider within centres and treatment
providers unique within centre
1 4% 0 0%
Undertaken in limited/exceptional circumstances only, e.g.
feasibility studies
1 4% 0 0%
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Table 4 Methods for managing clustering and learning by analysis
Question Category Response
statistics
n N n/
N%
6 a Assuming that you have stratified by centre, do you
combine by the stratification factor for the purpose
of analysis? If so how?
See Table 5 for further details.
Yes 24 44 55%
Pre-specified grouping rules at design stage 19 24 80%
Ad hoc approach, e.g. determined after design due to small
numbers per group
14 24 58%
Other grouping rule or further details provided 6 24 26%
No 17 44 39%
No response 3 44 7%
b Assuming that you have stratified by treatment
provider, do you combine by the stratification factor
for the purpose of analysis? If so how?
Yes 16 44 36%
Pre-specified grouping rules at design stage 12 16 75%
Ad hoc approach, e.g. determined after design due to small
numbers per group
7 16 44%
See Table 5 for further details. Other grouping rule or further details provided 5 16 31%
No 14 44 32%
No experience with trials of this type 1 44 2%
No response 13 44 30%
7 Does your Unit include centre in the statistical model
when comparing treatment?
Yes 39 44 89%
But only if it was used to stratify randomisation 18 39 46%
Always 6 39 15%
Sometimesa 15 39 38%
No, never 3 44 7%
No responseb 2 44 5%
a If yes, and assuming that the sample size allows
either, would you treat this effect as fixed or random?
See Supplementary Box 3 for further details.
Fixed or random, depending on circumstances 14 39 36%
Fixed 11 39 28%
Random 12 39 31%
No response 2 39 5%
8 Does your Unit include treatment provider in the
statistical model when comparing treatment?
Yes 26 44 59%
But only if it was used to stratify randomisation 8 26 31%
See Supplementary Box 4 for further details. Always 0 26 0%
Sometimesc 18 26 69%
No, never 13 46 30%
No responsed 5 44 11%
a If yes, and assuming that the sample size allows
either, would you treat this effect as fixed or random?
Fixed or random, depending on circumstances 4 26 15%
Fixed 2 26 8%
Random 18 26 69%
No response 2 26 8%
b If yes, has this effect ever been treated as
time-varying within the statistical model?
Yes 2 26 8%
No 21 26 81%
No response 3 26 12%
9 In each of the following scenarios, regardless of the
randomisation stratification approach, has a treatment
by centre or surgeon interaction investigated, in trials
that your Unit has run? Select all that apply.
See Supplementary Table 6 for further details.
A Large sample size,e recruiting in several centres, each Experience in trial type 35 44 80%
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Table 4 Methods for managing clustering and learning by analysis (Continued)
Question Category Response
statistics
n N n/
N%
with multiple treatment providers Centre 16 35 46%
Treatment provider 4 35 11%
Both 3 35 9%
Neither 20 35 57%
No experience in trial type 7 44 16%
No response 2 44 5%
B Small sample size,f With centres each recruiting 2 to 3
patients
Experience in trial type 30 44 68%
Centre 5 30 17%
Treatment provider 0 30 0%
Both 0 30 0%
Neither 25 30 83%
No experience in trial type 12 44 27%
No response 2 44 5%
C Recruiting in several centres, where treatment
providers treat patients across recruiting centres
(treatment provider is not unique to a centre)
Experience in trial type 15 44 34%
Centre 4 15 27%
Treatment provider 1 15 7%
Both 0 15 0%
Neither 11 15 73%
No experience in trial type 27 44 61%
No response 2 44 5%
D A trial investigating a surgical intervention, recruiting
from several centres, each with multiple treatment
providers
Experience in trial type 21 44 48%
Centre 5 19 24%
Treatment provider 3 19 14%
Both 1 19 5%
Neither 14 19 67%
No experience in trial type 19 44 43%
No response 4 44 9%
E Recruiting from several centres, each with multiple
treatment providers, comparing substantially
different interventions, e.g. surgery to an injection
Experience in trial type 14 44 32%
Centre 5 14 36%
Treatment provider 1 14 7%
Both 0 14 0%
Neither 9 14 64%
No experience in trial type 26 44 59%
No response 4 44 9%
In scenarios where Unit has experience, approaches to
stratification changes across scenario, i.e. within-Unit
variation to stratification
Different approaches across scenarios 12 44 27%
Same approach across all scenarios 24 44 55%
No response to Question 9 8 44 18%
10 a If a positive treatment effect is found, does your Unit
explore heterogeneity of treatment effects by centre?
See Supplementary Table 7 for further details.
Yes 32 44 73%
No 9 44 20%
No response 3 44 7%
i. If yes to a, do you explore by graphical display? Yes 31 32 97%
No 0 32 3%
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had been done either by pre-specified grouping rules at
the design stage (n = 19/24, 80%); by an ad hoc approach
(n = 14/24, 58%); or by other approaches: grouped cen-
tres where numbers are small [ID7, ID15]; site as a fixed
effect [ID8]; or:
“Depends. Either include as a stratifying factor
(small number of centres, large patient numbers) or
by including centre or treatment provider as a cluster.”
[ID32]
Regardless of the stratification approach used, very few
Units had never adjusted for centre in the statistical
model when comparing treatment (n = 3/44, 7%, Ques-
tion 7, Table 4 and Supplementary Box 3). Responders
from Units that did (39/44, 89%), did so using fixed ef-
fects (n = 11); random effects (n = 12); or, depending on
the circumstance, used either (n = 14). Two did not re-
spond. Reasons in favour of using fixed effects were ease
of interpretation and fewer assumptions associated with
it [ID27]; and random effects as:
“Usually an underlying assumption that centre may
be a surrogate for socioeconomic factors that may
affect outcome and/or treatment effect and so often
not happy to assume that there is an equal fixed
treatment effect across all sites.” [ID15]
In trials stratified by treatment provider, 36% also sub-
sequently adjusted the analysis (n = 16/44, 36%, Ques-
tion 6, Tables 4 and 5). Three-quarters did so in
accordance with pre-specified grouping rules (n = 12/16,
75%) or using a more ad hoc approach (n = 7/16, 44%).
Regardless of stratification approach used, 59% adjust
for treatment provider in the statistical model when
comparing treatment (n = 26/44, 59%, Question 8, Table
4 and Supplementary Box 4). The majority of responders
used a random effect (n = 18/26, 69%), with one provid-
ing reason:
“If treatment provider was included as stratification
factor it will be because we are concerned that the
provider will have an impact on outcome but also
because we would expect different population for dif-
ferent treatment providers.” [ID15]
When responders were asked to revisit the scenarios
in Table 1, this time to consider investigating treatment
by centre or treatment provider (Question 9, Table 4),
exploring treatment by centre was universally most com-
mon across all scenarios. Exploring treatment by pro-
vider was rare. Twelve responders provided free text to
explain their approaches for adjustment (Question 9,
Supplementary Table 6). General themes for additional
information provided were as follows: that the decision
Table 4 Methods for managing clustering and learning by analysis (Continued)
Question Category Response
statistics
n N n/
N%
No response 1 32 3%
ii. If yes to a, do you explore by analytical methods,
e.g. significance testing?
Yes 22 32 69%
No 5 32 16%
No response 5 32 16%
b If a positive treatment effect is found, does your Unit
explore heterogeneity of treatment effects by
treatment provider?
See Supplementary Table 8 for further details.
Yes 12 44 27%
No 23 44 52%
No response 9 44 20%
i. If yes to b, do you explore by graphical display? Yes 11 12 92%
No 0 12 0%
No response 1 12 8%
ii. If yes to b, would you explore by analytical
methods, e.g. significance testing?
Yes 9 12 75%
No 1 12 8%
No response 2 12 17%
a’Sometimes’ here is ’usually’—it is a rare exception where we don’t [ID10]
bNo Standard Operating Procedure in place [ID3]
c’Sometimes’ here is ’usually’—it is a rare exception where we don’t [ID10]
dNo experience in trials of this type [ID1]. Not applicable [ID2]
eWith centres each recruiting at least 10 patients
fWith centres each recruiting 2 to 3 patients
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is trial-dependent [ID6, ID14]; concerns around sample
size [ID6, ID7, ID39]; and, when explored, that this was
informal [ID5, ID8, ID14, ID32, ID38].
When comparing treatment interaction approaches
across scenarios within Units (Question 9, Table 4), 24
Units used the same approach across all scenarios, and
12 utilised a scenario-specific approach (same: n = 24/
44, 55%; different: n = 12/44, 27%). Eight had no experi-
ence in any of the suggested scenarios or did not re-
spond to the question.
Seventy-three percent of Units explored heterogeneity
by centre when a positive treatment effect is found (n =
32/44, 73%, Question 10a, Table 4), whereas fewer ex-
plored heterogeneity by treatment provider (n = 12/44,
27%, Question 10b, Table 4). Of those that do explore
heterogeneity for either effect, the majority did so by
graphical display (centre: n = 31/32; treatment provider:
n = 11/12). Many also explored by analytical methods,
for example significance testing (centre: n = 22/32; treat-
ment provider: n = 9/12). Supplementary Tables 6 and 7
provide further details.
Learning
Fifty-nine percent of CTUs included the treatment pro-
vider in the statistical model when comparing treatment
(n = 26/44, 59%), two of which had treated this as a
time-varying covariate (Question 8, Table 4), with one
specifying:
“Fairly crude by letting the number of procedures in
the trial increase the relevant surgeon’s experience
(ignoring procedures done outside of the trial of
course!)” [ID38]
Those that had not used a time-varying effect had ex-
perience in exploring learning through a sensitivity ana-
lysis [ID35] or secondary analyses [ID8, ID39], with one
specifying:
“Had we found evidence of learning, we would have
had awkward additional data summaries and pre-
sentations” [ID8]
Two responders had not considered such analyses
[ID7, ID23], and one provided time restrictions as a rea-
son for not doing so [ID30].
Discussion
This survey identifies the fact that, despite multicentre
trials being prominent across all CTUs, there is a UK-
wide variation of designing and analysing these trials
with respect to clustering and learning effects. Approxi-
mately half of Units changed their approach to design
and analysis when presented with five example trial sce-
narios, each with varying levels of complexity, such as
small sample size per centre and complex interventions,
such as surgery. This finding suggests that variation can
exist both across and within Units, suggesting that this
decision can depend on the type of trial being con-
ducted. Units indicate awareness of the potential meth-
odological challenges associated with the design and
analysis of multicentre trials, although the approaches
used and opinions on these vary. The high response rate
achieved provides insight into the general and current
practice of managing clustering and learning effects in
multicentre trials investigating varying types of interven-
tions. Whilst acknowledging that different approaches
may be more suitable to different trial types, they indi-
cate the need for a more unified approach to the design
Table 5 Other grouping rules when randomisation is stratified
by (a) centres or (b) treatment providers (Question 6)
Centre stratified:
ID4 Would normally analyse together but adjust for stratification
factors (which normally include centres) in analysis.
ID7 There will be instances where we have combined centres at
the analysis stage due to small numbers.
ID8 Different statisticians/trials do different things. Often site = fixed
effect and course within site = random effect. If too few within
site, then would combine.
ID14 Retain structure at analysis.
ID15 Have grouped by region/country where numbers are small.
Any adjustment should be documented in the Statistical
Analysis Plan, and final decision regarding appropriateness can
be discussed during blind review of data.
ID30 Have used both pre-specified and ad hoc approaches
(due to recruitment issues).
Not stratified by centre:
ID32 We either include as a stratification factor (small number of
centres, large patient numbers) or by including centre/provider
as a cluster.
Treatment provider stratified:
ID7 Thinking about complex intervention studies, we don’t usually
allow for a ’provider’ effect in the primary analyses, although
not necessarily explicitly stated in protocol—many of these
studies effectively have partial clustering. We’ve had recent
interesting discussions regarding provider effect in such trials,
with Chief Investigators strongly feeling that with standardised/
manualised intervention and training, it isn’t relevant.
ID15 Any adjustment should be documented in the Statistical
Analysis Plan, and final decision regarding appropriateness can
be discussed during blind review of data.
ID24 Experience with multiple treatment providers is in oncology
trials with different doctors delivering protocol treatment, e.g.
chemotherapy/radiotherapy. The actual treating doctor has not
been recorded on the Case Report Forms, hence all providers
implicitly combined within a centre.
ID30 Have used both pre-specified and ad hoc approaches (due to
recruitment issues).
ID39 Treatment providers combined by default—as we don’t
routinely distinguish them in the analysis.
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and analysis of trials where outcomes are associated with
the delivery of the intervention and/or more research in
this field.
When adjusting for clustering within the design, a higher
proportion than expected ran trials that did not stratify by
centre (52%). Most commonly, this was due to too many
centres and not enough participants within centre. Stratify-
ing by centre was most common in all scenarios, whilst
stratifying by treatment provider was consistently rare but
more common in trials with a surgical intervention. Strati-
fying by treatment provider raised pragmatic concerns, e.g.
concerns over relevance to research question, or provider
not known pre-randomisation. Whilst in some settings,
such as emergency treatment, advance knowledge of the
treatment provider will be unobtainable, advanced planning
may be possible in other settings, such as group therapy,
with guidance for practical issues like these available [13].
Half of the responders had adjusted by centre following
stratification by the same. Most commonly this was done
by pre-specified grouping rules established at the design
stage or using an ad hoc approach determined after design
due to small numbers per group. Regardless of stratification
approach, eight-tenths of responders had adjusted for
centre in the statistical model. There were mixed opin-
ions on how this adjustment was made, i.e. by fixed or
random effects with reasons provided for and against
both approaches. When a positive treatment effect is
found, three-quarters and one-third stated that they
then explore heterogeneity by centre and treatment pro-
vider respectively. All did so using graphical displays.
Managing learning by design through defining a mini-
mum level of expertise for health professionals partici-
pating in the trial [4] was most common, with almost all
responders (89%) applying this approach to studies
within their Unit. Less than a third indicated experience
in conducting expertise-based designs, a design that can
be particularly useful when comparing substantially dif-
ferent interventions. This finding suggests these designs
are more commonly implemented than suggested by the
literature [7, 14]. Concerns were raised that identifying
evidence of learning may lead to ’awkward additional
data summaries’.
Guidance on trial design and analysis does exist, with
the most relevant of these recommendations being expli-
citly incorporated into the survey questions [4, 6]
Supplementary Box 2. Additional documents within the
International Council for Harmonisation (ICH) Series
provide further guidance beyond ICH E9 [15, 16]. The
Consolidated Standards of Reporting Trials (CONSORT)
statement and relevant extensions provide direction
valuable at study design despite the document being de-
veloped to support reporting [17, 18]. The decision to
explore effects may, in part, be related to the intention
of the research in terms of how the results will be used,
and the PRECIS-2 tool has been developed to help with
this [19]. However, the ability to identify and explore
heterogeneity at the analysis stage is an important con-
sideration for generalisability for all trials.
Strengths of this study were that, although the survey
was limited to registered Units, responders represent
wide geographic coverage within the UK, spanning a di-
verse range of medical conditions and associated meth-
odologies. In addition, participating Units are known to
comply with required regulatory standards and meet ac-
ceptable standards of quality required by the UKCRC
CTU registration process [20]. All responders were ex-
perienced triallists who either were statistical lead at
their Unit or a nominated statistical representative. Pub-
licly funded trials cover a diversity of interventions [15]
and are generally not seeking a marketing authorisation
from the competent authorities, and this may impact the
approaches taken in line with heterogeneity of effects by
cluster or time. Limitations of this work are that it rep-
resents statistical practice within the UK in leading trial
centres, with global practice unknown. However, the
survey drew upon internationally accepted guidelines [4]
for best practice, and therefore the opinions and experi-
ences are applicable beyond the UK. Second, some of
the observed responses may have related to the different
types of trials that the CTUs conduct. Not all trials in-
clude interventions where there is learning. Indeed, one
would anticipate that many pragmatic large-scale trials
do not have ‘learning’ effects because they include inter-
ventions that are stabilised and in widespread use.
Whilst the survey allowed for free text responses, a more
focussed survey, achieved using qualitative research
methods, would be needed to examine these issues.
Third, the volume of studies designed by each Unit will
vary widely, and one responder per Unit may result in
experiences reported for larger Units not being indica-
tive of all studies run. However, responders were able to
complete the survey with additional support within their
Unit if deemed appropriate.
Conclusions
This survey is the first to report on the experience and
management approaches with regard to clustering effects
and the learning curve in multicentre randomised trials.
Importantly, responders, who were highly experienced in
the design and analysis of such studies, appear to have
awareness of when to make such considerations. Whilst
approaches to management are varied, and this variation
may be trial-dependent within Unit, reasons for ap-
proaches reported were provided and approaches justi-
fied. Historically, guidance on the design, analysis and
reporting of randomised controlled trials was developed
more generally to support consistency in approaches
across a more conventional randomised controlled trial
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[4, 15, 16], with the development of more intervention-
specific guidelines being established following these to
address the additional complexities across different types
of trials [11, 17, 18, 21]. Intervention-specific guidelines
may have led to the variation and justifications identified
in this survey. Results highlight the need for better
consistency between triallists. Agreeing principles to
guide trial design and analysis across a range of realistic
clinical scenarios should be considered and/or further
researched to establish optimal methods.
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